Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.

Axsome Therapeutics has experienced significant growth with its CNS disorder treatments, including recently approved drugs Auvelity for Alzheimer's agitation and Symbravo for migraines. While the stock has climbed 220% over three years and has strong revenue growth, the article cautions that reaching millionaire status from a single stock investment is unrealistic, recommending instead a diversified portfolio approach.